Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bioiberica Thyroid API is a natural desiccated thyroid (NDT) active pharmaceutical ingredient derived from porcine thyroid glands. It is designed for use as a primary ingredient in the formulation of thyroid hormone replacement therapies for the treatment of hypothyroidism. The API contains a natural combination of the hormones tetraiodothyronine (thyroxine, T4) and triiodothyronine (liothyronine, T3), which are essential for regulating metabolism, growth, and development. It is particularly targeted toward patients who prefer treatments of natural origin or those who continue to experience persistent symptoms despite standard synthetic levothyroxine monotherapy. Manufactured under GMP certification to European pharmaceutical standards, the product was launched in 2019 to leverage Bioiberica's expertise in animal-derived biological molecules.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bioiberica Thyroid API.